XML 103 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Fair value of financial assets and liabilities - Textual (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Nov. 30, 2018
USD ($)
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Fair value of financial assets and liabilities        
Settlement of future purchase obligation       $ (32,750)
Initial fair value of the anti-dilution right liability       1,639
Gain on extinguishment recognized $ 36,750     (36,750)
Transfers from level 1 to level 2, Assets 0   $ 0 0
Transfers from level 2 to level 1, Assets 0   0 0
Transfers from level 1 to level 2, Liabilities 0   0 0
Transfers from level 2 to level 1, Liabilities $ 0   0 0
Transfers into level 3 Assets     0 0
Transfers out of level 3 Assets     0 0
Transfers into level 3 liabilities     0 0
Transfers out of level 3 liabilities     $ 0 $ 0
Expected Dividend Rate        
Fair value of financial assets and liabilities        
Expected dividend yield     0  
Amgen Agreement        
Fair value of financial assets and liabilities        
Initial fair value of the anti-dilution right liability   $ 7,404    
Series A Preferred Stock | Amgen Agreement        
Fair value of financial assets and liabilities        
Share Issued under agreement | shares   3,205,128    
Second Tranche Closing        
Fair value of financial assets and liabilities        
Settlement of future purchase obligation   $ 32,750    
Second Tranche Closing | Series A Preferred Stock | Amgen Agreement        
Fair value of financial assets and liabilities        
Share Issued under agreement | shares   3,205,128    
Initial fair value of the anti-dilution right liability   $ 7,404